Initial Multicenter Experience with [ 161 Tb]Tb-PSMA in [ 177 Lu]Lu-PSMARefractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.125.270952 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Nuriye Ozlem Kucuk und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Nuclear Medicine, Ankara University, Ankara, Turkey. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
161Tb is a theranostic radionuclide that emits both β- particles and Auger electrons with high linear energy transfer, potentially enhancing cytotoxicity in micrometastatic disease. We report the first multicenter clinical experience of [161Tb]Tb-PSMA in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to [177Lu]Lu-PSMA therapy.
Methods
This prospective, multicenter study included 7 patients with mCRPC who had progressed despite prior androgen receptor pathway inhibitors, taxane-based chemotherapy, and at least 2 cycles of [177Lu]Lu-PSMA. All patients had PSMA-positive disease without any [18F]FDG-discordant lesions. Each received 2 cycles of [161Tb]Tb-PSMA (7.4 GBq per cycle, 6-wk interval). Response was assessed with [68Ga]Ga-PSMA PET/CT per RECIP 1.0 and prostate-specific antigen kinetics. Posttherapy dosimetry was performed using SPECT/CT imaging at 4 time points.
Results
Of the 7 patients, 4 (57%) demonstrated objective imaging response and 4 (57%) showed at least a 50% decline in prostate-specific antigen levels. Treatment was well tolerated, with only mild adverse events (grades 1-2) and no toxicity greater than grade 3. Organ dosimetry confirmed favorable absorbed dose distributions. Conclusion: [161Tb]Tb-PSMA demonstrated promising molecular and biochemical activity with a favorable safety profile in patients who had progressed after [177Lu]Lu-PSMA therapy. These preliminary findings support further investigation of 161Tb-based radiopharmaceuticals as next-generation therapeutic options for mCRPC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Department of Nuclear Medicine, Ankara University, Ankara, Turkey.
- Department of Nuclear Medicine, Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, Turkey; nazimcoskun@aybu.edu.tr.
- Faculty of Medicine, Department of Nuclear Medicine, Yeditepe University, Istanbul, Turkey.
- Department of Nuclear Medicine, Anadolu Medical Center, Istanbul, Turkey.
- Department of Nuclear Medicine, Bilkent City Hospital, Ankara Yildirim Beyazit University, Ankara, Turkey.
- Faculty of Medicine, Department of Nuclear Medicine, Manisa Celal Bayar University, Manisa, Turkey.
Zitieren
APA
Kucuk, N. O., Coskun, N., Araz, M., Alan Selcuk, N., Berberoglu, K., Ozdemir, E. C., Gumuser, F. G., Kuyumcu, S., Sezgin, C., Sanli, O., Sanli, Y., Sendur, M. A. N., & Urun, Y. (2025). Initial Multicenter Experience with [ 161 Tb]Tb-PSMA in [ 177 Lu]Lu-PSMARefractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270952
Vancouver
Kucuk NO, Coskun N, Araz M, Alan Selcuk N, Berberoglu K, Ozdemir EC, et al. Initial Multicenter Experience with [ 161 Tb]Tb-PSMA in [ 177 Lu]Lu-PSMARefractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.270952
BibTeX
@article{Kucuk2025,
author = {Kucuk, Nuriye Ozlem and Coskun, Nazim and Araz, Mine and Alan Selcuk, Nalan and Berberoglu, Kezban and Ozdemir, Elif Cingi and Gumuser, Fikriye Gul and Kuyumcu, Serkan and Sezgin, Ceren and Sanli, Ozgur and Sanli, Yasemin and Sendur, Mehmet Ali Nahit and Urun, Yuksel},
title = {Initial Multicenter Experience with [ 161 Tb]Tb-PSMA in [ 177 Lu]Lu-PSMARefractory Metastatic Castration-Resistant Prostate Cancer: Preliminary Results},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.125.270952}
}
EUVIMED